PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on June 27, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, June 27, 2024 -- PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy in stage III resected colon cancer, according to a study published online June 18 in the Journal of Clinical Oncology.

Jonathan A. Nowak, M.D., Ph.D., from Brigham and Women's Hospital in Boston, and colleagues prospectively examined whether adding the COX-2 inhibitor celecoxib to standard adjuvant chemotherapy reduces the risk of recurrence and improves survival for patients with stage III resected colon cancer. Preplanned subgroup analysis was performed by PIK3CA mutational status. Of the 1,197 tumors with available whole-exome sequencing data, PIK3CA gain-of-function mutations were identified in 259.

The researchers found that there was no significant improvement in disease-free survival (DFS) with celecoxib for all patients. On stratification by PIK3CA status, patients with gain-of-function mutations treated with celecoxib had significantly improved DFS (adjusted hazard ratio, 0.56 [95 percent confidence interval, 0.33 to 0.96]) compared with wildtype PIK3CA patients (adjusted hazard ratio, 0.89 [0.70 to 1.14]); the interaction was not significant. Patients with PIK3CA gain-of-function mutations had similarly improved overall survival (adjusted hazard ratio, 0.44 [0.22 to 0.85]) compared with wildtype patients (adjusted hazard ratio, 0.94 [0.68 to 1.30]).

"These findings represent the first clinical trial results to validate observational studies that have associated adjuvant aspirin and other nonsteroidal anti-inflammatory drug use, including COX-2 inhibitors, with improved survival for patients with PIK3CA-mutant colorectal cancer," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-06-28 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords